ArticleKidney international reports2026
Association of IgG N-Glycans With Adverse Outcomes in CKD.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: IgG N-glycosylation modulates inflammation and may influence chronic kidney disease (CKD). We investigated associations between IgG N-glycan patterns, kidney function, mortality, and kidney failure (KF) within the German CKD (GCKD) study. Methods: IgG N-glycan peaks were measured using ultrahigh-performance liquid chromatography in 4782 GCKD participants (estimated glomerular filtration rate [eGFR]: 30-60 ml/min per 1.73 m Results: The cohort comprised 4782 participants (mean age: 60 years, 40% women) with a median eGFR of 46 ml/min per 1.73 m Conclusion: IgG N-glycan patterns reflect inflammatory aging and associate with kidney function, mortality, and KF in CKD. These findings identify IgG N-glycans as potential immunologic biomarkers for CKD. Further validation is required to confirm causal relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.